US · Healthcare · Medical Devices
EPS came in at 1.02 against a street estimate of 0.96 — a beat of 6.3%.
Analysts rate LivaNova PLC a buy (8 buy, 3 hold, 0 sell out of 11) with an average price target of $89.10.
CONFIDENT LivaNova posted record Q2 revenue and EPS, raising full-year guidance on strong Cardiopulmonary (Essenz upgrade, oxygenator share gains) and Epilepsy (reimbursement, CORE data). Thermo Fisher supply deal addresses manufacturing bottleneck. Q2 2026 Europe drove Cardiopulmonary strength. U.S. CP growth moderate but tracking plan; Epilepsy +8% benefiting from reimbursement. Epilepsy Europe/RoW +15%. Analysts pressed manufacturing bottleneck, pricing sustainability in Epilepsy, and OSA timeline delay. Management emphasized Thermo Fisher deal removes long-term constraint, pricing upside extends into 2027, and OSA timing shift does not reflect product risk. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.96% |
| PRIMECAP Management Company | 7.57% |
| FMR Inc | 4.84% |
| AQR Capital Management LLC | 4.53% |
| Artisan Partners Limited Partnership | 4.04% |
| State Street Corp | 3.76% |
| American Century Companies Inc | 3.66% |
| Dimensional Fund Advisors, Inc. | 3.35% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 LIVANOVA PLC - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Revenue (Q2 2026): $390.6 million vs. $352.5 million (Q2 2025) – up 10.8% • Net Revenue ( | 2026-08-05 |
| Results announced · Q3 2026 LIVANOVA Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $390.6 million, up 10.8% reported (9.8% constant-currency) versus Q2 2025 • Q2 | 2026-08-05 |
| Shareholder vote results · Q2 2026 LIVANOVA PLC – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual General Meeting held: June 10, 2026 • All 10 shareholder proposals approved: Each resoluti | 2026-06-11 |
| Quarterly report · Q1 2026 LIVANOVA PLC - Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Net Revenue: $362.3 million (three months ended March 31, 2026), up 14% from | 2026-05-06 |
| Results announced · Q2 2026 LIVANOVA PLC – Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $362.3 million, up 14.3% reported / 11.1% constant-currency vs. Q1 2025 | 2026-05-06 |
| Proxy statement · Q2 2026 LIVANOVA PLC – 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect 11 directors individually (J. Christopher Barry, Fra | 2026-04-29 |
| Annual report FY2025 LIVANOVA PLC - ANNUAL REPORT SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: LivaNova PLC, publicly traded on Nasdaq under ticker LIVN • Fi | 2026-02-25 |
| Results announced · Q1 2026 LIVANOVA PLC - Q4 2025 EARNINGS SUMMARY HEADLINE NUMBERS • Full-year 2025 revenue: $1,388.1 million, up 10.7% reported / 9.7% constant-currency / 10 | 2026-02-25 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for LivaNova PLC — free to start.
Google PlayApp StoreData updated 2026-09-18.